PRELUDE THERAPEUTICS INC Earnings Per Share (Basic)
PRELUDE THERAPEUTICS INC (PRLD) reported Earnings Per Share (Basic) of -$0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC earnings per share, basic for the quarter ending 2026-06-30 was -$0.14.
- PRELUDE THERAPEUTICS INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.13.
- PRELUDE THERAPEUTICS INC earnings per share, basic for the quarter ending 2025-12-31 was -$0.21.
- PRELUDE THERAPEUTICS INC earnings per share, basic for the quarter ending 2025-09-30 was -$0.26.
- PRELUDE THERAPEUTICS INC earnings per share, basic for fiscal 2025 was -$1.29.
- PRELUDE THERAPEUTICS INC earnings per share, basic for fiscal 2024 was -$1.68.
- PRELUDE THERAPEUTICS INC earnings per share, basic for fiscal 2023 was -$2.02.
- PRELUDE THERAPEUTICS INC earnings per share, basic for fiscal 2022 was -$2.44.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.14 10-Q · filed 2026-08-11 | -$0.27 10-Q · filed 2026-08-11 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.13 10-Q · filed 2026-05-12 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.29 10-K · filed 2026-03-10 |
| 2025-09-30 | -$0.26 10-Q · filed 2025-11-12 | -$0.67 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.09 10-Q · filed 2025-11-12 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.41 10-Q · filed 2026-08-11 | -$0.83 10-Q · filed 2026-08-11 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.42 10-Q · filed 2026-05-12 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.68 10-K · filed 2026-03-10 |
| 2024-09-30 | -$0.43 10-Q · filed 2025-11-12 | -$0.88 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.30 10-Q · filed 2025-11-12 | -$1.77 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.46 10-Q · filed 2025-08-14 | -$0.87 10-Q · filed 2025-08-14 | -$1.35 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.80 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-03-31 | -$0.42 10-Q · filed 2025-05-06 | -$0.89 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.34 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.87 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2023-12-31 | -$0.48 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$0.93 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$1.46 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$2.02 10-K · filed 2025-03-10 |
| 2023-09-30 | -$0.45 10-Q · filed 2024-11-06 | -$0.99 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.55 10-Q · filed 2024-11-06 | -$2.14 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-06-30 | -$0.54 10-Q · filed 2024-08-12 | -$1.12 10-Q · filed 2024-08-12 | -$1.72 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$2.35 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-03-31 | -$0.58 10-Q · filed 2024-05-07 | -$1.18 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.81 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$2.39 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2022-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$1.23 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$1.81 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$2.44 10-K · filed 2024-02-15 |
| 2022-09-30 | -$0.63 10-Q · filed 2023-11-01 | -$1.21 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$1.84 10-Q · filed 2023-11-01 | -$2.54 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2022-06-30 | -$0.58 10-Q · filed 2023-08-03 | -$1.20 10-Q · filed 2023-08-03 | -$1.91 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$2.57 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2022-03-31 | -$0.63 10-Q · filed 2023-05-08 | -$1.33 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$1.99 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$2.58 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2021-12-31 | -$0.70 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.37 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.95 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$2.43 10-K · filed 2023-03-15 |
| 2021-09-30 | -$0.66 10-Q · filed 2022-11-14 | -$1.25 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.72 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$0.58 10-Q · filed 2022-08-09 | -$1.06 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |